Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay

被引:102
作者
Guedez, L
Rivera, AM
Salloum, R
Miller, ML
Diegmueller, JJ
Bungay, PM
Stetler-Stevenson, WG
机构
[1] NCI, Pathol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[2] NCI, Extracellular Matrix Sect, Ctr Canc Res, Bethesda, MD 20892 USA
[3] NCI, Vasc Biol Fac, Ctr Canc Res, Bethesda, MD 20892 USA
[4] NIH, Div Bioengn & Phys Sci, Off Res Serv, Bethesda, MD 20892 USA
关键词
D O I
10.1016/S0002-9440(10)64276-9
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
One of the major problems in angiogenesis research remains the lack of suitable methods for quantifying the angiogenic response in vivo. We describe the development and application of the directed in vivo angiogenesis assay (DIVAA) and demonstrated that it is reproducible and quantitative. This assay consists of subcutaneous implantation of semiclosed silicone cylinders (angioreactors) into nude mice. Angioreactors are filled with only 18 mul of extracellular matrix premixed with or without angiogenic factors. Vascularization within angioreactors is quantified by the intravenous injection of fluorescein isothiocyanate (FITC)-dextran before their recovery, followed by spectrofluorimetry. Angioreactors examined by immunofluorescence show cells and invading angiogenic vessels at different developmental stages. The minimally detectable angiogenic response requires 9 days after implantation and greater than or equal to50 ng/ml (P < 0.01) of either fibroblast growth factor-2 or vascular endothelial growth factor. Characterization of this assay system demonstrates that the FITC-labeled dextran quantitation is highly reproducible and that levels of FITC-dextran are not significantly influenced by vascular permeability. DIVAN allows accurate dose-response analysis and identification of effective doses of angiogenesis-modulating factors in vivo. TNP-470 potently inhibits angiogenesis (EC50 = 88 pmol/L) induced by 500 ng/ml of fibroblast growth factor-2. This inhibition correlates with decreased endothelial cell invasion. DIVAN efficiently detects differences in anti-angiogenic potencies of thrombospondin-1 peptides (25 mumol/L) and demonstrates a partial inhibition of angiogenesis (similar to40%) in a matrix metalloprotease (MMP)-2-deficient mouse compared with that in wild-type animals. Zymography of angioreactors from MMP-deficient and control animals reveals quantitative changes in MMP expression. These results support DIVAN as an assay to compare potencies of angiogenic factors or inhibitors, and for profiling molecular markers of angiogenesis in vivo.
引用
收藏
页码:1431 / 1439
页数:9
相关论文
共 28 条
  • [1] In vitro model for developmental progression from vasculogenesis to angiogenesis with a murine endothelial precursor cell line, MFLM-4
    Akeson, AL
    Brooks, SK
    Thompson, FY
    Greenberg, JM
    [J]. MICROVASCULAR RESEARCH, 2001, 61 (01) : 75 - 86
  • [2] Angiogenesis assays: Problems and pitfalls
    Auerbach, R
    Akhtar, N
    Lewis, RL
    Shinners, BL
    [J]. CANCER AND METASTASIS REVIEWS, 2000, 19 (1-2) : 167 - 172
  • [3] AUERBACH R, 2001, ASSAYS STUDY ANGIOGE, P91
  • [4] Basic fibroblast growth factor-induced angiogenic phenotype in mouse endothelium - A study of aortic and microvascular endothelial cell lines
    Bastaki, M
    Nelli, EE
    DellEra, P
    Rusnati, M
    MolinariTosatti, MP
    Parolini, S
    Auerbach, R
    Ruco, LP
    Possati, L
    Presta, M
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (03) : 454 - 464
  • [5] Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
    Bergers, G
    Brekken, R
    McMahon, G
    Vu, TH
    Itoh, T
    Tamaki, K
    Tanzawa, K
    Thorpe, P
    Itohara, S
    Werb, Z
    Hanahan, D
    [J]. NATURE CELL BIOLOGY, 2000, 2 (10) : 737 - 744
  • [6] Bogdanov A. Jr., 1999, Neoplasia (New York), V1, P438, DOI 10.1038/sj.neo.7900044
  • [7] BURBRIDGE MF, 2001, METHODS MOL MED ANGI
  • [8] Angiogenesis in cancer and other diseases
    Carmeliet, P
    Jain, RK
    [J]. NATURE, 2000, 407 (6801) : 249 - 257
  • [9] Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model
    Fang, JM
    Shing, Y
    Wiederschain, D
    Yan, L
    Butterfield, C
    Jackson, G
    Harper, J
    Tamvakopoulos, G
    Moses, MA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (08) : 3884 - 3889
  • [10] Folkman J, 2001, THROMB HAEMOSTASIS, V86, P23